Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5VLP
- Development stage
- Preclinical
- Lead developer
- Precision Virologics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Ad5VLP is a next-generation adenovirus-derived virus-like particle (VLP) platform designed for the rapid delivery of antigenic mRNA or protein cargo. Developed by researchers at Washington University in Saint Louis, the system utilizes a helper-virus-based approach where the adenoviral core protein pV is fused to the RNA-binding protein MCP to facilitate the encapsulation of foreign RNA, such as linear or circular mRNA. The platform combines the immunostimulatory properties of adenoviral structural proteins with the speed and scalability of VLP manufacturing, avoiding the lengthy rescue and amplification steps required for conventional recombinant adenoviral vectors. Preclinical studies have demonstrated its ability to induce robust antigen-specific humoral (B-cell) and cellular (T-cell) immune responses, making it a versatile candidate for infectious disease outbreak response and personalized cancer neoantigen vaccines.
- Other names
- adenovirus-derived virus-like particle
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CXADR (Coxsackievirus and adenovirus receptor)NeuraminidasePRR (Pattern recognition receptors)γδ TCR (T-cell receptor)Adenovirus serotype 5 structural proteins (Ad5 structural proteins)
Beyond the preview
Go deeper on Ad5VLP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad5VLP.